Cogentix Medical Company Profile (NASDAQ:CGNT)

About Cogentix Medical (NASDAQ:CGNT)

Cogentix Medical logoCogentix Medical, Inc. is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB). The Company also offers Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency. The PrimeSight flexible endoscopes are used in conjunction with the sterile, single-use microbial barrier known as the EndoSheath Protective Barrier. The PrimeSight endoscopy line also includes rigid endoscopes and portable peripherals, such as the video system and stroboscopy unit.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CGNT
  • CUSIP: N/A
  • Web:
  • Market Cap: $181.53 million
  • Outstanding Shares: 60,914,000
Average Prices:
  • 50 Day Moving Avg: $2.74
  • 200 Day Moving Avg: $2.06
  • 52 Week Range: $1.37 - $3.26
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -72.25
  • P/E Growth: -9.93
Sales & Book Value:
  • Annual Revenue: $53.65 million
  • Price / Sales: 3.28
  • Book Value: $1.04 per share
  • Price / Book: 2.78
  • EBITDA: $3.2 million
  • Net Margins: -35.88%
  • Return on Equity: -13.83%
  • Return on Assets: -10.53%
  • Current Ratio: 5.55%
  • Quick Ratio: 4.55%
  • Average Volume: 70,806 shs.
  • Beta: 0.72
  • Short Ratio: 2.03

Frequently Asked Questions for Cogentix Medical (NASDAQ:CGNT)

What is Cogentix Medical's stock symbol?

Cogentix Medical trades on the NASDAQ under the ticker symbol "CGNT."

How were Cogentix Medical's earnings last quarter?

Cogentix Medical, Inc. (NASDAQ:CGNT) issued its quarterly earnings results on Tuesday, August, 1st. The company reported $0.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.01) by $0.02. The firm had revenue of $14.06 million for the quarter, compared to analyst estimates of $13.90 million. Cogentix Medical had a negative return on equity of 13.83% and a negative net margin of 35.88%. View Cogentix Medical's Earnings History.

When will Cogentix Medical make its next earnings announcement?

Cogentix Medical is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Cogentix Medical.

Where is Cogentix Medical's stock going? Where will Cogentix Medical's stock price be in 2017?

1 analysts have issued 1 year price objectives for Cogentix Medical's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Cogentix Medical's share price to reach $5.00 in the next twelve months. View Analyst Ratings for Cogentix Medical.

Who are some of Cogentix Medical's key competitors?

Who are Cogentix Medical's key executives?

Cogentix Medical's management team includes the folowing people:

  • Uri Geiger, Chairman of the Board
  • Darin Hammers, President, Chief Executive Officer, Director
  • Brett A. Reynolds, Chief Financial Officer, Senior Vice President, Principal Financial Officer, Principal Accounting Officer, Secretary
  • Kenneth H. Paulus, Director
  • Cheryl Pegus M.D., Director
  • Lewis C. Pell, Director
  • Kevin H. Roche, Director
  • Nachum Shamir, Director

How do I buy Cogentix Medical stock?

Shares of Cogentix Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cogentix Medical's stock price today?

One share of Cogentix Medical stock can currently be purchased for approximately $2.89.

MarketBeat Community Rating for Cogentix Medical (NASDAQ CGNT)
Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  151
MarketBeat's community ratings are surveys of what our community members think about Cogentix Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cogentix Medical (NASDAQ:CGNT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (73.01% upside)
Consensus Price Target History for Cogentix Medical (NASDAQ:CGNT)
Price Target History for Cogentix Medical (NASDAQ:CGNT)
Analysts' Ratings History for Cogentix Medical (NASDAQ:CGNT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$5.00N/AView Rating Details
9/7/2016Roth CapitalUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Cogentix Medical (NASDAQ:CGNT)
Earnings by Quarter for Cogentix Medical (NASDAQ:CGNT)
Earnings History by Quarter for Cogentix Medical (NASDAQ CGNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.01)N/AView Earnings Details
8/1/2017Q2 2017($0.01)$0.01$13.90 million$14.06 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.01)($0.02)$13.14 million$12.95 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.14)$13.81 million$13.23 millionViewListenView Earnings Details
11/3/2015Q216($0.07)($0.06)$11.45 million$11.80 millionViewN/AView Earnings Details
8/10/2015Q116($0.10)($0.07)$11.34 million$11.20 millionViewListenView Earnings Details
5/14/2015Q415($0.06)($0.15)$49.10 million$7.00 millionViewListenView Earnings Details
2/3/2014Q3 14($0.03)$4.00 million$4.50 millionViewN/AView Earnings Details
8/12/2013Q1 2014($0.05)$34.00 million$3.70 millionViewN/AView Earnings Details
11/5/2012Q213($0.06)($0.07)$3.85 million$3.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cogentix Medical (NASDAQ:CGNT)
2017 EPS Consensus Estimate: ($0.02)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.01)($0.01)($0.01)
Q2 20171$0.00$0.00$0.00
Q3 20171($0.01)($0.01)($0.01)
Q4 20171$0.00$0.00$0.00
(Data provided by Zacks Investment Research)


Dividend History for Cogentix Medical (NASDAQ:CGNT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Cogentix Medical (NASDAQ:CGNT)
Insider Ownership Percentage: 62.70%
Institutional Ownership Percentage: 12.67%
Insider Trades by Quarter for Cogentix Medical (NASDAQ:CGNT)
Institutional Ownership by Quarter for Cogentix Medical (NASDAQ:CGNT)
Insider Trades by Quarter for Cogentix Medical (NASDAQ:CGNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/18/2016Kenneth A SametDirectorBuy25,000$2.47$61,750.00View SEC Filing  
6/10/2016Lewis C PellDirectorBuy13,291$0.95$12,626.45View SEC Filing  
6/1/2016Lewis C PellDirectorBuy894$0.75$670.50View SEC Filing  
5/31/2016Lewis C PellDirectorBuy500,000$0.79$395,000.00View SEC Filing  
5/21/2015Kevin H RocheDirectorBuy10,000$1.68$16,800.00View SEC Filing  
5/19/2015Kevin H RocheDirectorBuy10,000$1.60$16,000.00View SEC Filing  
2/20/2015Lewis C PellDirectorBuy20,000$0.51$10,200.00View SEC Filing  
2/19/2015Lewis C PellDirectorBuy10,000$0.48$4,800.00View SEC Filing  
2/18/2015Lewis C PellDirectorBuy30,000$0.45$13,500.00View SEC Filing  
2/13/2015Lewis C PellDirectorBuy20,000$0.47$9,400.00View SEC Filing  
2/11/2015Lewis C PellDirectorBuy35,000$0.46$16,100.00View SEC Filing  
12/23/2014Lewis C PellDirectorBuy80,000$0.85$68,000.00View SEC Filing  
12/22/2014Lewis C PellDirectorBuy40,000$0.86$34,400.00View SEC Filing  
9/23/2014Lewis C PellDirectorBuy5,000$0.99$4,950.00View SEC Filing  
9/19/2014Lewis C PellDirectorBuy3,900$1.00$3,900.00View SEC Filing  
9/17/2014Lewis C PellDirectorBuy5,000$1.02$5,100.00View SEC Filing  
9/16/2014Lewis C PellDirectorBuy5,000$1.07$5,350.00View SEC Filing  
9/12/2014Lewis C PellDirectorBuy23,300$1.04$24,232.00View SEC Filing  
9/8/2014Lewis C PellDirectorBuy30,000$1.04$31,200.00View SEC Filing  
9/3/2014Lewis C PellDirectorBuy30,000$0.98$29,400.00View SEC Filing  
8/27/2014Lewis C PellDirectorBuy10,000$0.92$9,200.00View SEC Filing  
8/26/2014Lewis C PellDirectorBuy30,000$0.93$27,900.00View SEC Filing  
8/19/2014Lewis C PellDirectorBuy22,900$0.98$22,442.00View SEC Filing  
8/13/2014Lewis C PellDirectorBuy43,420$0.91$39,512.20View SEC Filing  
8/8/2014Lewis C PellDirectorBuy27,500$0.95$26,125.00View SEC Filing  
6/6/2014Lewis C PellDirectorBuy10,000$1.13$11,300.00View SEC Filing  
5/21/2014Lewis C PellDirectorBuy5,000$1.09$5,450.00View SEC Filing  
5/16/2014Lewis C PellDirectorBuy14,197$1.02$14,480.94View SEC Filing  
11/18/2013Lewis C PellDirectorBuy6,296$0.91$5,729.36View SEC Filing  
11/15/2013Lewis C PellDirectorBuy20,000$0.90$18,000.00View SEC Filing  
9/18/2013Lewis C PellDirectorBuy16,000$0.91$14,560.00View SEC Filing  
9/13/2013Lewis C PellDirectorBuy5,000$0.92$4,600.00View SEC Filing  
9/10/2013Lewis C PellDirectorBuy5,000$0.92$4,600.00View SEC Filing  
9/9/2013Lewis C PellDirectorBuy4,564$0.95$4,335.80View SEC Filing  
9/6/2013Lewis C PellDirectorBuy5,000$0.97$4,850.00View SEC Filing  
9/3/2013Lewis C PellDirectorBuy11,432$0.97$11,089.04View SEC Filing  
8/29/2013Lewis C PellDirectorBuy1,100$0.98$1,078.00View SEC Filing  
8/27/2013Lewis C PellDirectorBuy11,596$0.97$11,248.12View SEC Filing  
8/26/2013Lewis C PellDirectorBuy14,965$0.97$14,516.05View SEC Filing  
8/19/2013Lewis C PellDirectorBuy25,025$0.94$23,523.50View SEC Filing  
8/15/2013Lewis C PellDirectorBuy15,000$0.92$13,800.00View SEC Filing  
6/28/2013Lewis C PellDirectorBuy28,400$1.00$28,400.00View SEC Filing  
6/27/2013Lewis C PellDirectorBuy45,048$0.99$44,597.52View SEC Filing  
3/15/2013Lewis C PellDirectorBuy30,000$1.14$34,200.00View SEC Filing  
3/12/2013Lewis C PellDirectorBuy45,000$1.10$49,500.00View SEC Filing  
3/7/2013Lewis C PellDirectorBuy60,000$1.09$65,400.00View SEC Filing  
3/4/2013Lewis C PellDirectorBuy20,000$1.06$21,200.00View SEC Filing  
2/26/2013Lewis C PellDirectorBuy66,266$1.01$66,928.66View SEC Filing  
2/21/2013Lewis C PellDirectorBuy25,000$0.99$24,750.00View SEC Filing  
2/19/2013Lewis C PellDirectorBuy5,000$0.99$4,950.00View SEC Filing  
2/7/2013Lewis C PellDirectorBuy9,000$0.99$8,910.00View SEC Filing  
2/5/2013Lewis C PellDirectorBuy25,000$1.01$25,250.00View SEC Filing  
2/1/2013Lewis C PellDirectorBuy10,000$1.09$10,900.00View SEC Filing  
12/27/2012Lewis C PellDirectorBuy10,000$1.07$10,700.00View SEC Filing  
12/17/2012Lewis C PellDirectorBuy21,600$1.10$23,760.00View SEC Filing  
12/13/2012Lewis C PellDirectorBuy18,961$1.10$20,857.10View SEC Filing  
12/10/2012Lewis C PellDirectorBuy6,656$1.10$7,321.60View SEC Filing  
12/3/2012Lewis C PellDirectorBuy8,360$1.10$9,196.00View SEC Filing  
11/30/2012Lewis C PellDirectorBuy45,748$1.10$50,322.80View SEC Filing  
11/27/2012Lewis C PellDirectorBuy3,593$1.10$3,952.30View SEC Filing  
11/23/2012Lewis C PellDirectorBuy39,357$1.09$42,899.13View SEC Filing  
11/19/2012Lewis C PellDirectorBuy57,050$1.08$61,614.00View SEC Filing  
11/14/2012Lewis C PellDirectorBuy100,000$1.15$115,000.00View SEC Filing  
11/12/2012Lewis C PellDirectorBuy24,852$1.17$29,076.84View SEC Filing  
9/6/2012Lewis C PellDirectorBuy10,000$1.37$13,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cogentix Medical (NASDAQ:CGNT)
Latest Headlines for Cogentix Medical (NASDAQ:CGNT)
Loading headlines, please wait.



Cogentix Medical (CGNT) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.